Emerging Therapeutic Potential of Cannabidiol (CBD) in Neurological Disorders: A Comprehensive Review

Behavioural Neurology, Год журнала: 2023, Номер 2023, С. 1 - 17

Опубликована: Окт. 12, 2023

Cannabidiol (CBD), derived from Cannabis sativa, has gained remarkable attention for its potential therapeutic applications. This thorough analysis explores the increasing significance of CBD in treating neurological conditions including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's which present major healthcare concerns on a worldwide scale. Despite lack available therapies, been shown to possess variety pharmacological effects preclinical clinical studies, making it an intriguing competitor. review brings together most recent findings endocannabinoid neurotransmitter systems, as well anti-inflammatory pathways, that underlie CBD's modes action. Synthesized efficacy safety assessments range illnesses are included, covering human trials, vitro animal models. The investigation includes how could protect neurons, control neuroinflammation, fend off oxidative stress, manage neuronal excitability. study emphasizes existing studies future possibilities research, addressing research issues such regulatory complications contradicting results, advocates further ideal dose methodologies. By emphasizing improve patient well-being, this presents revised viewpoint suitability intervention illnesses.

Язык: Английский

---

Comorbidity of attention deficit hyperactivity disorder in a patient with epilepsy: Staring down the challenge of inattention versus nonconvulsive seizures

Epilepsy & Behavior Reports, Год журнала: 2024, Номер 25, С. 100651 - 100651

Опубликована: Янв. 1, 2024

Epilepsy is a heterogeneous disorder of recurrent seizures which often comorbid with anxiety, depression, attention deficit hyperactivity (ADHD), intellectual disability (ID), and other psychiatric manifestations. Treating both epilepsy behavioral symptoms from disorders can result in polypharmacy interactions medications leading to worsened efficacy antiseizure due psychotropic effects worsening medication side effects. We aim suggest pragmatic strategies for the neurologist diagnosis management ADHD patients based on International League Against (ILAE) Pediatric Commission guidelines additional literature review. The screening tool choice validated country practice written language family, though various tools advantages disadvantages each will be discussed. Once diagnosed, recent safety data that Methylphenidate, Amphetamine, Atomoxetine are generally safe epilepsy. present case child discuss clinical signs, symptoms, treatment as well when refer psychiatry.

Язык: Английский

---

Unraveling the Endocannabinoid System: Exploring Its Therapeutic Potential in Autism Spectrum Disorder

NeuroMolecular Medicine, Год журнала: 2024, Номер 26(1)

Опубликована: Май 14, 2024

Abstract The salient features of autism spectrum disorder (ASD) encompass persistent difficulties in social communication, as well the presence restricted and repetitive facets behavior, hobbies, or pursuits, which are often accompanied with cognitive limitations. Over past few decades, a sizable number studies have been conducted to enhance our understanding pathophysiology ASD. Preclinical rat models proven be extremely valuable simulating analyzing roles wide range established environmental genetic factors. Recent research has also demonstrated significant involvement endocannabinoid system (ECS) pathogenesis several neuropsychiatric diseases, including In fact, ECS potential regulate multitude metabolic cellular pathways associated autism, immune system. Moreover, emerged promising target for intervention high predictive validity. Particularly noteworthy resent preclinical rodents, describe onset ASD-like symptoms after various pharmacological interventions targeting ECS, providing encouraging evidence further exploration this area.

Язык: Английский

---

Análise da utilização da Cannabis sativa na prática da clínica veterinária de pequenos animais: uma visão atual

PubVet, Год журнала: 2025, Номер 19(01), С. e1718 - e1718

Опубликована: Янв. 7, 2025

In the current scenario, Cannabis sativa has been highlighted due to increasing use of its components in treatment various pathologies, both human and veterinary medicine. The present study aims identify ways which is used Veterinary Medical Clinics today. For this, a methodology for bibliographic review. Finally, data found was compared proven, where Clinic verified chronic atopic dermatitis, epilepsy, travel-induced stress urothelial cancer dogs, addition as analgesics osteoarthritis. cats.

Язык: Английский

---

A Pilot Randomized Placebo-Controlled Crossover Trial of Medicinal Cannabis in Adolescents with Tourette Syndrome

Cannabis and Cannabinoid Research, Год журнала: 2025, Номер unknown

Опубликована: Март 14, 2025

Introduction: Medicinal cannabis (MC) has potential therapeutic effects in Tourette Syndrome (TS), however there been limited research adolescent patients. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled crossover trial MC adolescents with TS. Method: was phase I/II double-blind, cross-over comparing matched placebo aged 12-18 years The active medication Δ9-tetrahydrocannabinol (THC) 10 mg/mL and CBD 15 peppermint-flavored medium-chain triglyceride oil. dose titration schedule stratified into two participant weight bands: below 50 kg (max THC mg/day) or ≥50 20 mg/day). Each treatment lasted weeks, 4-week washout period. Results: Ten were (mean age 14.8 years, 50% male) seven completed full protocol. Two discontinued due adverse events (one on MC, one placebo) lost follow-up. most common event dizziness (67%). There no serious events. Among actively enrolled participants, protocol adherence excellent: visits 100%, blood test completions online questionnaire completion 97.6%. Medication acceptable 63.6%. Parents reported high degree design acceptability. On Clinical Global Impression-Improvement scale, three participants rated as much improved compared at weeks. Discussion: findings suggest that is feasible patients TS their families. A fully powered needed evaluate efficacy

Язык: Английский

---

Characterizing the Population of a Medical Cannabis Clinic in a Pediatric Hospital

Journal of Palliative Medicine, Год журнала: 2025, Номер unknown

Опубликована: Апрель 3, 2025

Background: Medical cannabis (MC) is increasingly in use due to recent cultural and political changes. Other than patients with Lennox-Gastaut Dravet syndrome, there inadequate literature provide evidence-based support for prescribing MC pediatric patients. Objectives: Characterize the population receiving an recommendation ambulatory palliative care setting quantify patient/family-reported outcomes. Design: Retrospective chart review of electronic medical record (EMR) data. Setting/Subjects: Total n = 46 consecutive advice regarding (n 42) a specialized clinic embedded division 4 inpatient midwestern U.S. hospital between 2019 2022. Measurements: Demographics, diagnosis, symptoms, adverse reactions, patient-reported outcomes, barriers abstracted from EMR. Results: Our sample included mean age 11.7 years (SD 5.4); 50% had neurological diagnosis 25); 37% 14) hematological/oncologic; 13% 6), chronic pain. The most common type recommended was 1:1 Cannabidiol (CBD): tetrahydrocannabinol (THC) tincture. There statistically significant decrease floor days cost. Totally, 35% were able or discontinue other medications. Thematic analysis identified four (product unavailable, difficulty obtaining state card, cost, organizational) subjective symptom improvement. Conclusions: These data characterize at our hospital. Positive outcomes noted across several domains. seems be associated lower health utilization, reduced polypharmacy, increased quality life used without events. In value-conscious environment, warrant further exploration.

Язык: Английский

---

Medicinal Cannabis for Emotional and Behavioural Symptoms: Parent and Physician Perspectives

Journal of Paediatrics and Child Health, Год журнала: 2025, Номер unknown

Опубликована: Апрель 8, 2025

Язык: Английский

---

Cannabinoids for Medical Purposes in Children: A Living Systematic Review

Acta Paediatrica, Год журнала: 2025, Номер unknown

Опубликована: Май 28, 2025

ABSTRACT Aim We developed a living systematic review (LSR) that will continuously map the safety and reported benefit data related to cannabinoid use for medical purposes in children. Methods MEDLINE, Embase, PsycInfo, Cochrane Library were searched from inception April 2023. Studies involving at least one child < 18 years who was administered plant‐derived or pharmaceutical cannabinoids as an intervention treatment conditions included. Results Of 37 189 identified citations, 276 studies included: 84 interventional, 131 observational, 54 surveys, 7 qualitative studies. Among interventional observational studies, common indications children refractory epilepsy ( n = 146 188 726 participants), cancer symptoms 30 208 753 autism spectrum disorder 1285 participants). Common purified cannabidiol (CBD) (78.6%, 66 5235 participants) with dose range of 2–50 mg/kg/day, tetrahydrocannabinol (6%, 5 148 2.5–10 mg/day (max nabiximols 32.4 mg) nabilone 267 0.5–2 mg/day. In randomised controlled trials, reduce seizure frequency ranging between 30% 50%. adverse events (> 20% studies) enrolling somnolence, diarrhoea, vomiting, decreased appetite. Conclusion These findings continue be updated inform practice reveal knowledge gaps future research.

Язык: Английский

---

New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(12), С. 3567 - 3567

Опубликована: Июнь 18, 2024

Epilepsy is a disorder characterized by abnormal brain neuron activity, predisposing individuals to seizures. The International League Against (ILAE) categorizes epilepsy into the following groups: focal, generalized, generalized and unknown. Infants are most vulnerable pediatric group condition, with cause of development being attributed congenital developmental defects, white matter damage, intraventricular hemorrhage, perinatal hypoxic-ischemic injury, stroke, or genetic factors such as mutations in Sodium Channel Protein Type 1 Subunit Alpha (SCN1A) gene. Due risks associated this we have investigated how latest pharmacological treatments for children impact reduction complete elimination We reviewed literature from 2018 2024, focusing on age month 18 years old, some studies including well older individuals. significance review present compile research findings antiseizure drugs (ASDs), their effectiveness, dosing, adverse effects population, which can contribute selecting best drug particular patient. medications described shown significant efficacy safety studied patient group, outweighing observed effects. main aim provide comprehensive summary current state knowledge regarding newest pharmacotherapy childhood epilepsy.

Язык: Английский

---

Effects of Medical Cannabis Treatment for Autistic Children on Anxiety and Restricted and Repetitive Behaviors and Interests: An Open-Label Study

Cannabis and Cannabinoid Research, Год журнала: 2024, Номер unknown

Опубликована: Июль 24, 2024

The literature supports the benefits of medical cannabis for core and comorbid symptoms in autistic individuals anxiety-related without autism. However, no study has specifically investigated how cannabidiol (CBD)-rich affects anxiety subtypes children or its relationship with restricted repetitive behaviors interests (RRBI). Understanding effects CBD-rich treatment on RRBI could offer more precise approaches to managing reducing frequency children.

Язык: Английский

---